^
    Back
    Association details:
    Biomarker:CSF3R T618I
    Cancer:Chronic Neutrophilic Leukemia
    Drug:dasatinib (c-KIT inhibitor, Bcr-abl tyrosine kinase inhibitor, Src kinase inhibitor, EphA2 receptor antagonist, PDGFR β antagonist)
    Direction:Resistant
    Evidence:
    Evidence Level:
    Resistant: D – Preclinical
    New
    Source:
    N Engl J Med
    Title:

    Oncogenic CSF3R Mutations in Chronic Neutrophilic Leukemia and Atypical CML

    Excerpt:
    Treatment with dasatinib had a dramatic effect on S783fs-driven colony formation, with a 50% inhibitory concentration (IC50) of approximately 1 nM (Fig. 2A). The T618I mutant was relatively insensitive to dasatinib...
    DOI:
    https://dx.doi.org/10.1056%2FNEJMoa1214514